ConductScience.org, home

Paper41598623

Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.

Kawczak P and 1 other. J Clin Med, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone. Papers, record 41598623. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41598623

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.
PubMed
Journal
J Clin Med
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-01-31
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kawczak PPiotrhttps://orcid.org/0000-0003-3902-2744
2Bączek TTomaszhttps://orcid.org/0000-0001-6468-1974

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References225

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141217772Lutetium Lu 177 vipivotide tetraxetan: A literature review.J Oncol Pharm Pract2026https://conductscience.org/library/papers/41217772PubMed
238614820EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.Eur Urol2024https://conductscience.org/library/papers/38614820PubMed
321807635Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.Clin Cancer Res2011https://conductscience.org/library/papers/21807635PubMed
423228172Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med2013https://conductscience.org/library/papers/23228172PubMed
539577422Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.Cancer Cell2024https://conductscience.org/library/papers/39577422PubMed
635599144Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.Eur Urol Oncol2022https://conductscience.org/library/papers/35599144PubMed
739060912Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.Drugs2024https://conductscience.org/library/papers/39060912PubMed
830310278Targeted nonviral gene therapy in prostate cancer.Int J Nanomedicine2018https://conductscience.org/library/papers/30310278PubMed
939123395Development of a Multidisciplinary Care Pathway for Fracture Prevention in Men with Prostate Cancer at Initiation of Androgen Deprivation Therapy.Cancers (Basel)2024https://conductscience.org/library/papers/39123395PubMed
1031482746The current status of the clinical utility of liquid biopsies in cancer.Expert Rev Mol Diagn2019https://conductscience.org/library/papers/31482746PubMed
1140299225Advances in Targeted Therapy for Metastatic Prostate Cancer.Curr Treat Options Oncol2025https://conductscience.org/library/papers/40299225PubMed
1235273651Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.Ther Adv Med Oncol2022https://conductscience.org/library/papers/35273651PubMed
1323863050Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med2013https://conductscience.org/library/papers/23863050PubMed
1431732676Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.J Nucl Med2020https://conductscience.org/library/papers/31732676PubMed
1532820953The potential of PSMA-targeted alpha therapy in the management of prostate cancer.Expert Rev Anticancer Ther2020https://conductscience.org/library/papers/32820953PubMed
1619487300Adaptive therapy.Cancer Res2009https://conductscience.org/library/papers/19487300PubMed
1729635390RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.Ann Oncol2018https://conductscience.org/library/papers/29635390PubMed
1840864353Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.Curr Oncol Rep2025https://conductscience.org/library/papers/40864353PubMed
1940940844The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials.Cancers (Basel)2025https://conductscience.org/library/papers/40940844PubMed
2041038711Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients.Cancer Res Commun2025https://conductscience.org/library/papers/41038711PubMed

See all 225 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42745883PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies.Front Cell Dev Biol2026https://conductscience.org/library/papers/42745883PubMed
42729212Association of selected ELAC2, MSR1, RNASEL and KLK3 polymorphisms with prostate cancer susceptibility in a Hungarian cohort.Pathol Oncol Res2026https://conductscience.org/library/papers/42729212PubMed
41827159Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.J Clin Med2026https://conductscience.org/library/papers/41827159PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AR367PubTator's text mininghttps://conductscience.org/library/genes/367NCBI Gene
FOLH12346PubTator's text mininghttps://conductscience.org/library/genes/2346NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41598623

GET https://conductscience.org/api/papers/v1/41598623/references?page=2